Lacidipine
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
C08CA09
CAS registry number (Chemical Abstracts Service)
0103890-78-4
Chemical Formula
C26-H33-N-O6
Molecular Weight
346
Therapeutic Categories
Antihypertensive agent
Calcium channel blocker
Chemical Name
3,-5-Pyridinedicarboxilic acid,4-[2-[3-(1,1-dimetyletoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimetyl-,dietyl ester, (E)-
Foreign Names
- Lacidipinum (Latin)
- Lacidipin (German)
- Lacidipine (French)
- Lacidipino (Spanish)
Generic Names
- Lacidipina (OS: DCIT)
- Lacidipine (OS: USAN, DCF, BAN, JAN)
- GR 43659 X (Glaxo) (IS)
- GX 1048 (Glaxo) (IS)
- Lacidipine (PH: BP 2018)
Brand Names
- Aponil
Glaxo Allen, Italy - Lacibloc
Ultramed, Philippines - Lacicard
Aristopharma, Bangladesh - Lacidac
Delta Pharma, Egypt - Lacidipin Belupo
Belupo, Croatia (Hrvatska) - Lacidipin Double-E Pharma
Copharma, Denmark - Lacidipin Teva
Teva, Denmark; Teva, Lithuania - Lacidipina Rivopharm
Rivopharm, Italy - Lacidipine
Doc Generici, Malta; Dr. Reddy's, United Kingdom; Rivopharm UK, United Kingdom - Lacidipine Double-E Pharma
Alpha-Medical, Croatia (Hrvatska); Double-E Pharma, Lithuania; Double-E Pharma Limited, Netherlands - Lacidipine Teva
Teva Nederland, Netherlands; Teva Pharmaceuticals, Poland - Lacidipino Teva
Teva, Spain - Lacimen
GlaxoSmithKline, Spain - Lacipil
Glaxo, Bulgaria; Glaxo Group, Romania; Glaxo Wellcome, Portugal; GlaxoSmithKline, Bulgaria; GlaxoSmithKline, Estonia; GlaxoSmithKline, Egypt; GlaxoSmithKline, Spain; GlaxoSmithKline, Georgia; GlaxoSmithKline, Hong Kong; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Italy; GlaxoSmithKline, Lithuania; GlaxoSmithKline, Latvia; GlaxoSmithKline, Mexico; GlaxoSmithKline, Malaysia; GlaxoSmithKline, Philippines; GlaxoSmithKline, Poland; GlaxoSmithKline, Turkey; GlaxoSmithKline, Taiwan; GlaxoSmithKline, Venezuela; GlaxoSmithKline A.B.E.E., Greece; GlaxoSmithKline Brasil, Brazil; GSK, Czech Republic; GSK, Slovakia; Wellcome Limited, Bosnia & Herzegowina; GlaxoSmithKline China Investment, China - Lacipil 2 mg
GlaxoSmithKline, Hungary - Lacipil 4 mg
GlaxoSmithKline, Hungary - Lacirex
Laboratori Guidotti, Italy - Lacitens
GlaxoSmithKline A.B.E.E., Greece - Lacivas
Sun, India - Lacydyna
Alpha-Medical, Croatia (Hrvatska); Rivopharm, Poland - Ladip
Glaxo Allen, Italy - Lanidiem
Samil, South Korea - Lapixen
Biofarm, Poland - Lasyn
Synmosa, Taiwan - Lodipine
Egyphar, Egypt - Midotens
Boehringer Ingelheim, Mexico - Monopin
Pliva, Bosnia & Herzegowina; Pliva, Croatia (Hrvatska) - Motens
Boehringer Ingelheim, Greece; Boehringer Ingelheim España, Spain; GlaxoSmithKline UK, United Kingdom - Prelum
double-e pharma, Latvia - Sileping
Hayao Pharmaceutical Group Holding, China - Sinopil
GlaxoSmithKline, India - Viapres
Crinos, Italy
Glossary
| Term | Definition |
|---|---|
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
